Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.
Pfizer has chosen three of Synexus' clinical research centres in South Africa to be a part of its 100-site INSPIRE programme based on the sites’ experience and audit history.
The DEA has approved AMRI’s Burlington facility to work with Schedule 2 controlled substances, placing it in a competitive position to win contract manufacturing bids, the company says.
MPI Research, inviCRO and 3D Imaging are partnering to combine their imaging tools at a new center in Michigan aimed at large biopharma clients.
CRO Parexel’s massive backlog could position the company for continued revenue growth moving forward, top executives said at recent conferences.
The European Commission has welcomed the publication of the list of Indian API makers issued with “written confirmations” of quality by the CDSCO.
Phyton Biotech has received European approval for a version the cancer drug API docetaxel whose production does not rely on the scarce yew tree extract used in traditional manufacturing methods.
Eisai has announced plans to expand its global packaging capabilities with a £8m ($12.5m) facility in the UK.
Sanofi has ended production at a historic London facility and says it plans to turn the site into a dedicated science park.
Europe could face drug shortages if the US is not granted exemption from new API import requirements, according to a US chemical industry trade association.